Addendum: Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma

Eugene J. Vaios; Kristen A. Batich; Anne F. Buckley; Anastasie Dunn-Pirio; Mallika P. Patel; John P. Kirkpatrick; Ranjit Goudar; Katherine B. Peters

doi:10.18632/oncotarget.28292

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma

PDF | How to cite

Oncotarget. 2022; 13:1165-1165. https://doi.org/10.18632/oncotarget.28292

Metrics: PDF 768 views | ?

Eugene J. Vaios¹, Kristen A. Batich², Anne F. Buckley³, Anastasie Dunn-Pirio⁴, Mallika P. Patel⁵, John P. Kirkpatrick¹, Ranjit Goudar⁶ and Katherine B. Peters^7,8

¹Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
²Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA
³Department of Pathology, Duke University Medical Center, Durham, NC, USA
⁴Department of Neurology, UC San Diego Health, San Diego, CA, USA
⁵Department of Pharmacy, Duke University Medical Center, Durham, NC, USA
⁶Virginia Oncology Associates, Norfolk, VA, USA
⁷Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
⁸Department of Neurology, Duke University Medical Center, Durham, NC, USA

Published: October 20, 2022

Copyright: © 2022 Vaios et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: Informed consent was obtained from each patient and the study was approved by our institution.

Original article: Oncotarget. 2022; 13:576–582. DOI: https://doi.org/10.18632/oncotarget.28222

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28292

Publication Alerts

Post-Publication Promotion

Addendum:

Addendum: Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma